Research and Clinical Trials on Olanzapine (Zyprexa)

Olanzapine (Zyprexa) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Olanzapine (Zyprexa).

• Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
  Status: Recruiting, Condition Summary: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Obesity; Metabolic Syndrome
• Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia
• Pilot Study of Topiramate and Olanzapine in the Prevention of Weight Gain in Children and Adolescents With Bipolar Disorder
  Status: Completed, Condition Summary: Bipolar Disorder; Weight Gain
• Olanzapine Treatment of Patients With Bipolar I Disorder
  Status: Active, not recruiting, Condition Summary: Depression, Bipolar
• Haloperidol vs Olanzapine for the Management of ICU Delirium
  Status: Recruiting, Condition Summary: Delirium; Agitation
• Cardio Risk of Acute Schizophrenia Olanzapine Duke
  Status: Withdrawn, Condition Summary: Schizophrenia; Schizoaffective Disorder
• Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
  Status: Completed, Condition Summary: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder
• Olanzapine in Patients With Advanced Cancer and Weight Loss
  Status: Recruiting, Condition Summary: Advanced Cancer; Weight Loss
• Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
  Status: Completed, Condition Summary: Manic or Mixed Episode Associated With Bipolar I Disorder
• Long-Term Olanzapine Treatment in Children With Autism
  Status: Recruiting, Condition Summary: Autism
• Study of Amantadine for Weight Stabilization During Olanzapine Treatment
  Status: Recruiting, Condition Summary: Psychotic Disorder; Schizophreniform Disorder; Schizophrenia; Schizoaffective Disorder; Mood Disorders With Psychotic Features
• Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
  Status: Completed, Condition Summary: Bipolar Disorder
• Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
  Status: Terminated, Condition Summary: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
• Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
  Status: Active, not recruiting, Condition Summary: Schizophrenic Disorders; Schizoaffective Disorder
• A Controlled Study of Olanzapine in Children With Autism
  Status: Recruiting, Condition Summary: Autistic Disorder

 

Get These Clinical Trials as a Newsfeed

Olanzapine:             

Current Research Literature on Olanzapine (Zyprexa)

Here are abstracts for some of the latest research articles to have appeared on Olanzapine (Zyprexa):

[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection.]

Gastroenterol Hepatol. 2009 Nov 13;
Gómez Espín R, Sánchez Quiles I, Hallal H, Plaza J

Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

J Affect Disord. 2009 Nov 13;
Bond DJ, Kauer-Sant'anna M, Lam RW, Yatham LN
BACKGROUND: Numerous studies have demonstrated an association between bipolar disorder (BD) and obesity. However, these reports are limited by retrospective or cross-sectional designs, and the assessment of patients with lengthy illnesses. Prospective data, and data on weight gain early in the course of BD, are lacking. METHODS: We prospectively measured weight gain and laboratory metabolic indices over 12months in 47 patients with BD receiving maintenance treatment following their first manic episode, and in 24 age- and gender-matched healthy subjects. RESULTS: Although approximately two-thirds of patients had experienced previous depressive or hypomanic episodes, there was no difference between patients and healthy subjects in mean body mass index or rates of overweight or obesity at recovery from the first mania. Mean weight gain over 12months was 4.76kg in patients and 1.50kg in healthy subjects (p=0.047). Combined rates of overweight and obesity at 6months and 12months exceeded 50% in patients, and were almost double those of healthy subjects. Logistic regression demonstrated that weight gain in the first 6months was significantly associated with male gender and prescription of olanzapine or risperidone. Patients who were obese at 6months and/or 12months had significantly greater mean serum triglyceride levels and fasting glucose levels than non-obese patients. LIMITATIONS: This was a naturalistic study. CONCLUSIONS: Even in patients with previous depressions and hypomanias, clinically significant weight gain in BD begins following the first manic episode, suggesting that it is primarily related to treatment with mood stabilizers and second-generation antipsychotics. However, the very small number of patients in our sample who were medication-free precludes a meaningful analysis of the degree to which weight gain might be an inherent feature of post-manic BD.

Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia.

Schizophr Res. 2009 Nov 11;
Mattai A, Chavez A, Greenstein D, Clasen L, Bakalar J, Stidd R, Rapoport J, Gogtay N
BACKGROUND: Little is known about the effects of antipsychotic medications on gray matter (GM) in schizophrenia. Although clozapine remains the most effective antipsychotic medication in treatment-refractory cases, it is unknown whether it has a differential effect on GM development. METHODS: In an exploratory analysis, we used automated cortical thickness measurements and prospectively scanned childhood-onset schizophrenia (COS) patients who were maintained on one medication. Two atypical antipsychotic medications, clozapine (n=12, 37 scans) and olanzapine (n=12, 33 scans) were compared with respect to effects on cortical development, in contrast to GM trajectories of matched controls. RESULTS: There were no significant differences in the trajectories of cortical thickness between the two treatment groups with the exception of a small circumscribed area in the right prefrontal cortex, where the olanzapine group showed thicker cortex. As expected, both groups showed thinner GM compared to matched controls. CONCLUSIONS: Although these analyses do not rule out effects of antipsychotic medications on GM development in schizophrenia, they show no differential effect between clozapine and olanzapine on GM trajectory.

Olanzapine-induced tardive oculogyric crisis.

J Clin Psychopharmacol. 2009 Dec; 29(6): 604-6
Praharaj SK, Jana AK, Sarkar S, Sinha VK

30 Days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.

J Clin Psychopharmacol. 2009 Dec; 29(6): 576-83
Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, Moles A
The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.